Evogene (EVGN) Director Nir Nimrodi Receives 10,000 Option Award

What Happened

• Nir Nimrodi, a director of Evogene Ltd. (EVGN), was granted 10,000 stock options on September 4, 2026. The grant is a derivative award (Form 4 code A) with no cash paid at grant. The exercise price is NIS 1.75 per share, stated as approximately $0.58 per share based on the Bank of Israel exchange rate on the grant date.

Key Details

• Transaction date: 2026-09-04 (reported on Form 4 filed 2026-09-30; filing appears late vs. the usual 2-business-day requirement).
• Grant: 10,000 options; exercise price NIS 1.75 (~$0.58 at NIS 3.0050/USD).
• Vesting: 25% per quarter starting on the grant date; fully vested by 2027-09-04 (one year).
• Plan: Options granted under Evogene’s 2021 Share Incentive Plan.
• Holdings after transaction: not specified in the provided summary (the row is included for informational purposes).
• Filing exhibits/remarks: Exhibit 24.1 (Power of Attorney) included.

Context

• This was a compensation grant of options (an award), not a cash purchase or sale. The options give the right to buy shares later at the stated exercise price; exercising later would require payment of that price and may have tax implications. The grant was disclosed on a Form 4 filed roughly 26 days after the grant date.